Genzyme Oncology

Genzyme Corporate

Oncology Home

Genzyme Websites

Discovery and Collaboration
Genzyme Oncology is building a foundation in cancer treatment with a strong focus on discovery in both antibody and small molecule based therapies. Our lead products are Campath® (alemtuzumab), a humanized monoclonal antibody and Clolar® (clofarabine) a small molecule nucleoside analog. Ongoing discovery utilizes a broad range of target discovery, target validation and drug development technologies. Genzyme Oncology is also working in active collaboration with partner companies and academic institutions to identify and develop new therapies.

Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
Genzyme Corp. (Nasdaq: GENZ) announced on Dec 5, 2007 that the company has completed enrollment of a phase 2 clinical trial examining the safety and effectiveness of Clolar® (clofarabine) in previously untreated, older adult patients with acute myelogenous leukemia (AML) who are unlikely to benefit from standard induction therapy. Data from this study are expected to provide substantial evidence for expanding the current product label into adult AML. More>



			Our Marketed Products Find out about products currently available.



			Our Research Track our progress in research and development.



			Our Clinical Trials Learn about trials currently under way.



			Our Product Pipeline Find out about our products in development.

Genzyme Oncology is focused on developing and commercializing novel treatments for cancer patients through promising internal research and active external collaborations. Genzyme Oncology's product development expertise and strong research program provide a solid base for building a sustainable and competitive oncology business. Genzyme Oncology has a full pipeline of innovative drug candidates derived from diverse technologies. The combination of new, sophisticated molecular diagnostics with targeted therapeutics is considered hopeful in revolutionizing cancer treatment and improving patient outcomes.

Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
Genzyme Corporation (Nasdaq: GENZ) and Bioenvision, Inc. (Nasdaq: BIVN) announced on October 22, 2007 that Bioenvision stockholders had voted to approve the acquisition of the company by Genzyme at a reconvened special shareholder meeting in New York. More>